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Abstract
In this study, we report the synthesis and biological evaluation of a variety of α- and β-hydroxy substituted amino acid
derivatives as potential amino acid subunits in inhibitors of GABA uptake transporters (GATs). In order to ensure that the
test compounds adopt a binding pose similar to that presumed for related larger GAT inhibitors, lipophilic residues were
introduced either at the amino nitrogen atom or at the alcohol function. Several of the synthesized compounds were found to
exhibit similar inhibitory activity at the GAT subtypes mGAT2, mGAT3, and mGAT4, respectively, as compared with the
reference N-butylnipecotic acid. Hence, these compounds might serve as starting point for future developments of more
complex GAT inhibitors.
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Introduction
Gamma-aminobutyric acid (GABA) is the most abundant
inhibitory neurotransmitter in the mammalian central nervous
system (CNS) (Bowery and Smart 2006), with up to 40% of
synapses estimated to be GABAergic (Meldrum and Chap-
man 1999). Deficient GABAergic neurotransmission is
assumed to play a decisive role in the pathogenesis of several
severe neurological diseases, including Alzheimer’s disease
(Lanctôt et al. 2004), depression (Kalueff and Nutt 2007),
epilepsy (Treimann 2001), and neuropathic pain (Daemen
et al. 2008). A promising therapeutical approach for the
treatment of these diseases exists in the inhibition of the
transport molecules responsible for the removal of GABA
from the synaptic cleft, resulting in the prolongation of the
effect exerted by the available GABA (Krogsgaard-Larsen
et al. 1991). Belonging to the solute carrier 6 (SLC6)
transporter gene family, these membrane-bound proteins
termed GABA transporters (GATs) use the co-transport of
sodium ions for the translocation of the substrate against the
chemical gradient (Kristensen et al. 2011). The nomenclature
of the four GAT subtypes depends on the species the trans-
porters are cloned from. When originating from mouse brain
cells, the GAT subtypes are termed mGAT1–4. For all other
species, including humans, an alternate nomenclature is used
which has also been adopted by the Human Genome Orga-
nisation, denoting the transporters GAT1 (=mGAT1), BGT1
(=mGAT2), GAT2 (=mGAT3), and GAT3 (=mGAT4)
(Madsen et al. 2009). Hereafter the nomenclature referring to
the murine transporters will be applied as the biological test
system used in our group is based on these. mGAT1 and
mGAT4 are the most abundant GATs in the mammalian
CNS, with the former being predominantly located on pre-
synaptic neuronal membranes mediating the neuronal GABA
uptake, whereas mGAT4, which is mainly expressed on glia
cells, is responsible for the glial GABA uptake (Minelli et al.
1996; Jin et al. 2011). The other two GAT subtypes, mGAT2
and mGAT3, are primarily located in the periphery, with the
highest densities being found in liver and kidneys, and hence
are thought to not play any significant role in the termination
of GABAergic signalling in the CNS (Zhou et al. 2012).
The first parent compound selectively targeting GATs was
4,5,6,7-tetrahydroixoxazolo[4,5-c]pyridin-3-ol (THPO, 1,
Table 1, entry 1) (White et al. 2002), which is derived from
muscimol, an alkaloid isolated from fly agaric (Amanita
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muscaria) that can be considered an bioisostere of GABA
(Corvey et al. 1994). Replacement of the isoxazol-3-ol partial
structure of THPO with a carboxylic acid function led to the
more potent GAT inhibitors guvacine (2, Table 1, entry 2)
and nipecotic acid [(R)-3,(S)-3 Table 1, entry 3–4] (Krogs-
gaard-Larsen et al. 2000). However, these cyclic GABA
analogues still lacked inhibitory potency and subtype selec-
tivity (Table 1, entry 1–4). Moreover, due to being present in
the zwitterionic state under physiological conditions, guvacine
(2) and nipecotic acid [(R)-3,(S)-3] are hardly able to cross the
blood brain barrier (BBB), which strongly limits any potential
therapeutic application (Seth et al. 2018).
When bulky, lipophilic residues were introduced at the
nitrogen atom, this led to compounds with not only increased
lipophilicity and hence improved BBB penetration, but also
with significantly higher inhibitory potency. In this context,
compounds possessing a diaryl methyl or a biaryl unit as
lipophilic domain which is connected to the nipecotic acid
partial structure via a flexible linker of 3–5 atoms proved to be
highly potent and selective mGAT1 inhibitors, with the
respective pIC50 values rising from ~5 to almost 7 as compared
with unsubstituted (R)-nipecotic acid. Among these com-
pounds, Tiagabine (Gabatril®, 4, Table 1, entry 5) stands out
for being the only GAT inhibitor that has been approved for
clinical use (Nielsen et al. 1991).
In a similar way the introduction of a lipophilic residue
consisting of a triarylmethyl group, which is linked to the
nipecotic acid subunit via a spacer of three atoms, furnishes
mGAT4 selective inhibitors, with (S)-SNAP-5114 con-
stituting the prototypic representative of this group (5, Table
1, entry 6) (Dhar et al. 1994). Remarkably, the (S)-isomer 5
exhibits higher inhibitory potency than the respective (R)-
isomer, running contrary to what is observed for the
unsubstituted nipecotic acid [(R)-3, (S)-3] as well as for
mGAT1 inhibitors such as Tiagabine (4).
Interestingly, small amino acids including β-alanine (6,
Table 2, entry 1), isoserine (7a, Table 2, entry 2), 2,3-diami-
nopropionic acid (8, Table 2, entry 3) and (Z)-4-aminobut-2-
enoic acid (9, Table 2, entry 4) also show moderate biological
activity at mGAT3 and mGAT4 that is comparable to that
exerted by (R)-nipecotic acid [(R)-3, Table 1, entry 3], while
being distinctly less potent inhibitors of mGAT1 (Kragler et al.
2005). Thus, substitution of the nipecotic acid partial structure
in the lead compound (S)-SNAP-5114 (5) with a (S)-2-
hydroxy-2-[(R)-pyrrolidin-2-yl]acetic acid unit, which can be
understood as rigidized derivative of rac-isoserine (7a), led to
Table 1 GAT inhibitors
Entry Compound GABA uptake inhibition (pIC50 ± SEM)
a
mGAT1 mGAT2 mGAT3 mGAT4
1 1 3.0 2.5 <2.5 <2.5
2 2 4.87 ± 0.06 3.31 ± 0.03 4.59 ± 0.05 4.59 ± 0.05
3 (R)-3 5.19 ± 0.03 3.39 ± 0.05 4.76 ± 0.05 4.95 ± 0.05
4 (S)-3 4.24 ± 0.05 3.13 ± 0.14 3.83 ± 0.04 3.63 ± 0.06
5 4 6.88 ± 0.12 50%b 64%b 73%b
6 5 4.07 ± 0.09 62%b 5.29 ± 0.04 5.71 ± 0.20
aResults of the [3H]GABA uptake assays are given as pIC50 ± SEM
bPercentages represent remaining [3H]GABA uptake in presence of 100 µM test compound
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compound 10, which displays significantly improved subtype
selectivity in favour of mGAT4. Unfortunately, this structure
variation is also accompanied by a moderate decrease of
inhibitory potency (pIC50= 5.18 ± 0.05, Table 2, entry 5) as
compared with the parent compound 5 (pIC50= 5.71 ± 0.20,
Table 1, entry 6) (Steffan et al. 2015).
For the development of mGAT4 inhibitors with increased
subtype selectivity, this study hence aims to identify further
cyclic and acyclic 2- and 3-hydroxyamino acids as possible
alternatives to the nipecotic acid partial structure present in the
scaffold of important mGAT4 inhibitors such as 5. In this
context, the hydroxyl function plays a crucial role as it may
enable additional interactions with the target, e.g., by estab-
lishing hydrogen bridges, hence increasing binding enthalpy.
Proceeding from the basic structure of isoserine 7a, it was
intended to implement several structural modifications,
including elongation of the carbon chain by insertion of
methylene groups at various positions, and the rigidization of
the molecule by integrating the amino acid backbone into lar-
ger heterocycles. Accordingly, a set of compounds featuring
both variations and thus deviating from the original isoserine
(7a) structure should be synthesized and biologically evaluated
(Scheme 1).
Despite the stereochemistry of amino acids such as
nipecotic acid [(R)-3, (S)-3] being known to represent an
important factor when it comes to the biological activity of
mGAT4 inhibitors, we opted for the synthesis of the target
compounds in racemic form as this provides information
about the biological activity of both enantiomers.
According to the results of molecular modelling experi-
ments previously performed by us for mGAT1 (Wein et al.
2016), small inhibitors such as nipecotic acid adapt a
binding pose at which the amino nitrogen atom is facing
towards the intracellular space. However, if bulky, lipophilic
Table 2 GAT inhibitors
Entry GABA uptake inhibition (pIC50 ± SEM)
a
compound mGAT1 mGAT2 mGAT3 mGAT4
1 6 2.59 ± 0.03 3.48 ± 0.11 4.66 ± 0.06 4.46 ± 0.13
2 7a 2.33 ± 0.05 3.39 ± 0.11 4.87 ± 0.05 4.78 ± 0.14
3 8 3.11 ± 0.02 3.50 ± 0.12 4.66 ± 0.08 5.05 ± 0.02
4 9 2.99 ± 0.04 3.67 ± 0.08 4.95 ± 0.04 5.04 ± 0.06
5 10 80%b 64%b 70%b 5.18 ± 0.05
aFor consistency the values determined in our research group are listed
bRemaining [3H]GABA uptake at 100 µM compound concentration
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moieties are introduced at the nitrogen atom, as it is the case
with Tiagabine (4, Table 1, entry 5), the binding pose is
altered in a way that the nitrogen atom is orientated towards
the extracellular site, with the lipophilic side chain looming
into the extracellular vestibule, although the position of the
carboxylic acid function remains largely unchanged
(Scheme 2). Using the example of a N-butyl residue, Wein
et al. demonstrated that even the presence of small N-
substituents is sufficient to cause this change of the binding
mode. Although no reliable in silico models exists so far for
the other GAT subtypes, it seems highly likely that these
findings also apply to mGAT2-4. Thus, following this
assumption, all parent compounds included in this study
were also evaluated for their inhibitory potential as N-butyl
derivatives in order to ensure that the orientation of the
parent compounds in the binding pocket corresponds to the
orientation they would have as part of larger molecules
comprising a lipophilic domain.
In addition, unsubstituted α- and β-hydroxyamino acids
exhibiting higher biological activity than their corre-
sponding N-butyl derivatives should in addition be sub-
stituted at the alcohol function. In detail, the alcohol
function should be provided with a 4,4′,4″-trimethoxy-





Scheme 2 Postulated binding poses of nipecotic acid (3, a) and Tiagabine (4, b) at mGAT1
Scheme 1 Planned structure variations of isoserine (7a)
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is a characteristic structural motif of mGAT4 inhibitors
such as 5 and 10. According to the model pointed out
above, this might allow the amino acid substructure to stay
in the position with the nitrogen atom facing towards the
intracellular space, which would evidently be more
favourable than the antagonal orientation found in the N-
substituted amino acids. At the same time, the newly
introduced lipophilic domain might be accommodated in
the vestibule, which is known to contribute in general
significantly to inhibitory potency and selectivity of GAT
inhibitors (compare Table 1, entries 3 and 4 with 6).
Materials and methods
Chemistry
Moisture-sensitive reactions were carried out in oven-dried
glassware under inert gas atmosphere. Commercially avail-
able starting materials were used without further purification.
Tetrahydrofuran (THF) was freshly distilled from sodium
benzophenone ketyl. All other solvents were distilled prior to
use. Microwave reactions were carried out with Biotage
Initiator™. Flash column chromatography was performed on
Merck silica gel 60 (mesh 0.040–0.063 mm) as stationary
phase; thin-layer chromatography (TLC) was carried out on
Merck silica gel 60 F254 sheets. Preparative MPLC was
performed using a Buechi instrument (C-605 binary pump
system, C-630 UV detector at 254 nm and C-660 fraction
collector) and a Sepacore B-685 (26 V, 230mm) glass col-
umn equipped with YMC Gel Triart Prep C18-S (12 nm,
5–20 µm). 1H and 13C NMR spectra were, unless stated
otherwise, recorded at rt with JNMR-GX (JEOL 400 or
500MHz) or Bruker BioSpin Avance III HD (400 or
500MHz) and integrated with the NMR software MestRe-
Nova. Deuterated solvents for NMR, which included
CD2Cl2, CDCl3, MeOD, D2O, and 1,1,2,2-tetrachloroethane-
d2, were purchased from Eurisotop, Saint-Aubin, France.
NaOD was purchased from Sigma-Aldrich Chemie GmbH,
Munich, Germany. IR samples were measured as KBr pellets
or film with Perkin-Elmer FT-IR 1600. HRMS data were
obtained with JMS-GCmate II (EI, Jeol) or Thermo Finnigan
LTQ FT Ultra (ESI, Thermo Finnigan).
General procedure for the synthesis of the β-hydroxyamino
acid esters (GP1)
A solution of lithium-HMDS in MTBE (0.97M) was cooled
to −78 °C and anhydrous ethyl acetate (EtOAc, 1.0 eq) was
added dropwise. After complete addition the mixture was
stirred for 25 min and a solution of ketone (1.0 eq) in dry THF
was added. The reaction mixture was allowed to slowly warm
up to −10 °C, quenched with brine, diluted with H2O and
extracted thrice with CH2Cl2. The combined CH2Cl2 phases
were dried over sodium sulfate (Na2SO4) and concentrated in
vacuum to yield the crude product.
General procedure for the deprotection and N-butylation of
the amino acid amides and amino acid esters (GP2)
A mixture of the benzyl or benzhydryl-protected amino acid
derivative, palladium on charcoal (10% Pd, 0.1 eq) and
butyraldehyde (2.5 eq) in EtOH was stirred vigorously
under 15 bar hydrogen pressure for 16 h, filtered over
Cealite® and reduced in vacuum.
General procedure for the hydrolysis of the amides and
esters (GP3)
A mixture of carboxamide or ester and barium hydroxide
octahydrate (2.0–2.4 eq) was stirred under reflux conditions
(carboxamides) or at rt (esters) in EtOH/H2O 1:1 for the
appropriate time. Carbon dioxide was passed through until
no further precipitate formed. The suspension was filtered
over a cotton wool pad and a syringe filter (Perfect-Flow®,
WICOM Germany GmbH, PTFE, 0.2 µM) and reduced in
vacuum. The residue was solved in distilled water (2.0 ml)
and lyophilized.
General procedure for the N-butylation of the acyclic amino
acids (GP4)
The amino acid (1.0 eq) and KOH (2.0 eq) were suspended in
EtOH and H2O was added until the reaction mixture became
homogeneous. 1-Bromobutane (0.9 eq) was added dropwise.
After stirring at rt for 16 h the reaction mixture was reduced in
vacuum. The crude compound was purified by MPLC (elu-
ent: MeOH/H2O 1:9).
General procedure for the protection of the acyclic amino
acids I (GP5a)
A solid, well-grounded mixture of the amino acid (1.0 eq)
and phtalic anhydride (1.0 eq) was heated to 140 °C,
resulting in a colourless melting. After 30 min, the reaction
mixture was cooled to rt and re-dissolved in EtOAc
(300 ml). The solution was washed with 1M sodium
hydrogen sulfate solution (100 ml), water (3 × 100 ml), and
brine (100 ml). The organic layer was dried over Na2SO4,
filtered, and concentrated in vacuum. The resulting residue
was solved in anhydrous MeOH (250 ml) and 2M HCl in
Et2O (250 ml) was added. The mixture was stirred at rt until
TLC indicated complete consumption of the educt and
reduced in vacuum. The crude compound was purified by
Medicinal Chemistry Research (2020) 29:1321–1340 1325
flash column chromatography on silica (eluent: CH2Cl2/
EtOAc 9:1).
General procedure for the protection of the acyclic amino
acids II (GP5b)
A solid, well-grounded mixture of the amino acid (1.0 eq)
and phtalic anhydride (1.0 eq) was heated to 140 °C,
resulting in a colourless melting. After 30 min, the reaction
mixture was cooled to rt, solved in anhydrous MeOH
(250 ml) and 2M HCl in Et2O (250 ml) was added. The
mixture was stirred at rt until TLC indicated complete
consumption of the educt and reduced in vacuum. The
crude compound was purified by flash column chromato-
graphy on silica (eluent: CH2Cl2/EtOAc 9:1).
General procedure for the formation of the ether function
(GP6)
tert-Butyl(2-iodoethoxy) diphenylsilane (1.4 eq) and
Ag2CO3 (4.0 eq) were added to a suspension of the amino
acid derivative (1.0 eq) in toluene (10.0 ml). The reaction
mixture was stirred in a pressure tube at 120 °C until TLC
indicated complete consumption of the amino acid deriva-
tive, cooled to rt, filtered through a paper filter and reduced
in vacuum. The residue was purified by flash column
chromatography on silica (eluent: pentane/Et2O 7:3).
General procedure for cleavage of the TBDPS protecting
group (GP7)
The TBDPS-protected compound (1.0 eq) was solved in
THF/pyridine 9:1 (v/v) in a polypropylene tube. A 70%
solution of HF-pyridine (5.0 eq) was added dropwise at
0 °C. The suspension was stirred at rt and the progress of
the reaction was monitored by TLC. After complete con-
sumption of the educt phosphate buffer (pH= 6.0, 1.0 M,
100 ml) was added and the mixture was extracted with
ethyl acetate (100 ml). The organic phase was washed with
water (100 ml) and brine (100 ml), dried over MgSO4 and
reduced in vacuum. The crude product was purified by
flash column chromatography on silica (eluent: CH2Cl2/
EtOAc 65:35).
General procedure for the coupling of the alcohol with
4,4′,4″-trimethoxytrithyl chloride (GP8)
The alcohol (1.0 eq) was solved in pyridine. Dimethyl-
formamide (DMF, 1 drop) and 4,4′,4″-trimethoxytrithyl
chloride (1.8 eq.) were added. The mixture was stirred at
55 °C for 16 h and reduced in vacuum. The crude product
was purified by flash chromatography on silica (eluent
Et2O/pentane: 6:4).
General procedure for the deprotection of the acyclic
amino acid derivatives I (GP9a)
12 M NaOH (2.0 eq) was added to a solution of the
protected compound (1.0 eq) in MeOH (15.0 ml). After
stirring for 16 h at rt, 1,2-diaminoethane (7.0 eq) was
added and the mixture was heated in a microwave for
16 h at 140 °C. Finally, the reaction mixture was reduced
in vacuum and purified by MPLC (eluent: MeOH/
H2O 7:3).
General procedure for the deprotection of the acyclic
amino acid derivatives II (GP9b)
12M NaOH (2.0 eq) was added to a solution of the pro-
tected compound (1.0 eq) in MeOH (15.0 ml). After stirring
for 16 h at rt, the mixture was freeze-dried. 1,2-Diami-
noethane (7.0 eq) was added and the mixture was heated in
a microwave for 16 h at 140 °C. Finally, the reaction mix-
ture was reduced in vacuum and purified by MPLC (eluent:
MeOH/H2O 7:3).
3-(Butylamino)-2-hydroxypropanoic acid (7b)
GP4 was followed using 7a (90mg, 0.86mmol), EtOH
(1.0 ml), KOH (114mg, 1.72mmol), 1-bromobutane
(106mg, 0.774 mmol). The desired compound was obtained
as amorphous white solid (110mg, 79%). 1H NMR
(400MHz, MeOD) δ= 4.07 (dd, J= 8.1, 4.7 Hz, 1H,
COOHCH), 3.24 (dd, J= 12.5, 4.7 Hz, 1H, COOHCHCH2),
3.06 (dd, J= 12.5, 8.1 Hz, COOHCHCH2), 3.04–2.99
(m, 2H, CH3CH2CH2CH2), 1.74–1.57 (m, 2H, CH3CH2CH2),
1.43 (m, 2H, CH3CH2CH2), 0.99 (t, J= 7.4 Hz, 3H,
CH3CH2CH2) ppm;
13C NMR (101MHz, MeOD) δ= 177.2
(COOH), 68.9 (COOHCH), 52.2 (COOHCHCH2), 48.6
(NCH2CH2CH2CH3), 29.2 (NCH2CH2CH2CH3), 20.8
(NCH2CH2CH2CH3), 13.9 (NCH2CH2CH2CH3) ppm; IR
(KBr): ṽ= 3397, 1463, 1390, 1135, 1110, 770 cm−1; HRE-
SIMS m/z (pos): 162.1123 C7H16NO3 (calcd. 162.1130).
Methyl 3-(1,3-dioxoisoindolin-2-yl)-2-hydroxypropanoate
(7c)
GP5b was followed using 3-amino-2-hydroxypropionic
acid 7a (1.10 g, 10.5 mmol), phthalic anhydride (1.56 g,
10.5 mmol) in MeOH (80.0 ml) and 2M HCl in Et2O
(80.0 ml). The desired compound was obtained as amor-
phous white solid (2.00 g, 76%). 1H NMR (400MHz,
CDCl3) δ= 7.90–7.83 (m, 2H, NCOCarCHarCHar),
7.78–7.69 (m, 2H, NCOCarCHarCHar), 4.50 (td, J= 6.5,
5.1 Hz, 1H, NCH2CH), 4.08 (dd, J= 14.1, 5.1 Hz, 1H,
NCH2), 4.02 (dd, J= 14.1, 6.4 Hz, 1H, NCH2), 3.82 (s, 3H,
OCH3), 3.07 (d, J= 6.8 Hz, 1H, OH) ppm; 13C NMR
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(101MHz, CDCl3) δ= 173.2 (COOCH3), 168.4 (NCO),
134.3 (NCOCarCHarCHar), 132.0 (NCOCarCHarCHar), 123.7
(NCOCarCHarCHar), 68.7 (NCH2CH), 53.2 (OCH3), 41.2
(NCH2) ppm; IR (HBr): ṽ= 3497, 1747, 1700, 1464, 1440,
1396, 1310, 1231, 1095, 983, 883, 722 cm−1; HRESIMS:
m/z (pos): 272.0529 C12H11NO5Na (calcd. 272.0535).
Methyl 3-{2-[(tert-butyldiphenylsilyl)oxy]ethoxy}-3-{-(1,3-
dioxoisoindolin-2-yl})propanoate (7d)
GP6 was followed using 7c (4.3 mmol, 1072mg), tert-butyl
(2-iodoethoxy)diphenylsilane (6.02mmol, 2374mg), Ag2CO3
(17.2 mmol, 4743mg), toluene (15.0 ml), 4d. The desired
compound was obtained as yellow oil (1882 mg, 82%). 1H
NMR (500MHz, CD2Cl2) δ= 7.85–7.78 (m, 2H, NCO-
CarCHarCHar), 7.76–7.68 (m, 2H, NCOCarCHarCHar),
7.66–7.57 (m, 4HrCHar), 7.47–7.33 (m, 6H, CHar), 4.38 (dd,
J= 6.8, 6.0 Hz, 1H, NCH2CH), 4.02 (dd, J= 14.0,
6.8 Hz,1H, NCH2), 3.98 (dd, J= 14.0, 6.0 Hz, 1H, NCH2),
3.78–3.68 (m, 6H, CHOCH2CH2Si, OCH3), 3.58–3.49 (m,
1H, CHOCH2CH2Si), 0.94 (s, 9H, CCH3) ppm;
13C NMR
(126MHz, CD2Cl2) δ= 171.3 (COOCH3), 168.4 (NCO),
136.1 (Car), 134.6 (Car), 134.0 (Car), 132.5 (Car), 130.2 (Car),
128.2 (Car), 123.8 (Car), 76.7 (NCH2CH), 72.4 (OCH2CH2Si),
63.9 (OCH2CH2Si), 52.7 (OCH3), 39.9 (NCH2CH), 27.0
(SiCCH3), 19.4 (SiC) ppm; IR (film): ṽ= 2930, 1755, 1700,
1427, 1395, 1208, 1111, 703 cm−1; HRESIMS m/z (pos):
554.1970 C30H33NO6SiNa (calcd. 554.1975).
Methyl 3-(1,3-dioxoisoindolin-2-yl)-3-(2-hydroxyethoxy)
propanoate (7e)
GP7 was followed using 7d (737mg, 1.35 mmol), THF/
pyridine 9:1 (10.0 ml), HF-pyridine (1.93 g, 6.75 mmol).
The desired compound was obtained as a yellow oil
(350 mg, 84%). 1H NMR (400MHz, CD2Cl2) δ= 7.89–7.82
(m, 2H, NCOCarCHarCHar), 7.81–7.72 (m, 2H, NCO-
CarCHarCHar), 4.25 (dd, J= 6.5, 5.5 Hz, 1H, NCH2CH),
4.00 (dd, J= 14.0, 6.5 Hz, 1H, NCH2), 4.05 (dd, J= 14.0,
5.5 Hz, 1H, NCH2), 3.75 (s, 3H, OCH3), 3.70–3.54 (m, 4H,
OCH2CH2OH) ppm;
13C NMR (101MHz, CD2Cl2) δ=
171.55 (COOCH3), 168.6 (NCO), 134.8 (NCOCarCHar
CHar), 132.5 (NCOCarCHar), 123.9 (NCOCarCHar), 76.9
(NCH2CH), 73.4 (OCH2CH2OH), 62.0 (OCH2CH2OH),
52.9 (OCH3), 40.0 (NCH2) ppm; IR (film): ṽ= 3474, 1774,
1770, 1429, 1396, 1213, 1029, 720 cm−1; HRESIMS m/z
(pos): 294.0973 C14H16NO6 (calcd. 294.0978).
Methyl 3-{1,3-dioxoisoindolin-2-yl}-2-{2-[tris(4-
methoxyphenyl)methoxy]ethoxy}propanoat (7f)
GP8 was followed using 7e (367 mg, 1.25 mmol), DMF (1
drop), pyridine (4.0 ml), 4,4′,4″-trimethoxytrithyl chloride
(856 mg, 2.25 mmol). The desired compound was
obtained as yellow oil (705 mg, 90%). 1H NMR
(500 MHz, CD2Cl2) δ= 7.87–7.76 (m, 2H, NCOCarCHar
CHar), 7.76–7.67 (m, 2H, NCOCarCHarCHar), 7.26–7.17
(m, 6H, CarCHarCHarCarOCH3), 6.81–6.68 (m, 6H,
CarCHarCHarCarOCH3), 4.38 (dd, J= 7.3, 5.5 Hz, 1H,
NCH2CH), 4.06 (dd, J= 14.0, 7.4 Hz, 1H, NCH2), 4.00
(dd, J= 14.1, 5.5 Hz, 1H, NCH2), 3.77 (s, 9H, CarOCH3),
3.74 (s, 3H, COOCH3), 3.73 (ddd, J= 10.5, 5.4, 3.5 Hz,
1H, OCH2CH2OCCar),3.52 (ddd, J= 10.4, 6.9,
3.5 Hz, 1H, OCH2CH2OCCar), 3.16 (ddd, J= 10.4, 6.9,
3.5 Hz, 1H, OCH2CH2OCCar), 3.06 (ddd, J= 10.3, 5.3,
3.5 Hz, 1H, OCH2CH2OCCar) ppm;
13C NMR (126 MHz,
CD2Cl2) δ= 171.3 (COOCH3), 168.4 (NCO), 158.9
(CCarCHarCHarCarOCH3), 137.2 (CCarCHar), 134.6
(NCOCarCHarCHar), 132.5 (NCOCar), 130.2 (CH3O-
CarCHarCHar), 123.8 (NCOCarCHarCHar), 113.5
(CCarCHarCHarCarOCH3), 86.2 (OCH2CH2OCCar), 76.8
(NCH2CH), 70.9 (OCH2CH2OCCar), 63.5 (OCH2-
CH2OCCar), 55.7 (CarOCH3), 52.7 (COOCH3), 40.0
(NCH2CH) ppm; IR (film): ṽ= 1776, 1607, 1506, 1464,
1395, 1249, 1176, 1034, 827 cm−1; HRESIMS m/z (pos):
648.2210 C36H35NO9Na (calcd. 648.2210).
3-Amino-2-{2-[tris(4-methoxyphenyl)methoxy]ethoxy}
propanoic acid (7g)
GP9a was followed using 7f (192 mg, 0.300mmol), MeOH
(3.0 ml), 12M NaOH (0.05ml), 1,2-diaminoethane (126 mg,
2.10mmol). The desired compound was obtained as amor-
phous white solid (123mg, 83%). 1H NMR (500MHz, 0.1M
NaOD/MeOD) δ= 7.46–7.14 (m, 6H, CH3OCarCHarCHar),
7.05–6.65 (m, 6H, CH3OCarCHarCHar), 3.85 (ddd, J= 10.6,
5.2, 4.4 Hz, 1H, OCH2CH2OCCar), 3.81 (dd, J= 6.4, 3.8 Hz,
1H, NCH2CH), 3.77 (s, 9H, OCH3), 3.52 (ddd, J= 10.9, 6.7,
4.1 Hz, 1H, OCH2CH2OCCar), 3.31 (m, 1H, OCH2CH2OC-
Car), 3.24 (ddd, J= 10.0, 5.4, 4.1 Hz, 1H, OCH2CH2OCCar),
2.93 (dd, J= 13.4, 3.8 Hz, 1H, NCH2), 2.85 (dd, J= 13.4,
6.4 Hz, 1H, NCH2) ppm;
13C NMR (126MHz, 1M NaOD/
MeOD) δ= 180.8 (COOH), 179.2 (CH3OCarCHarCHarCar),
159.9 (CH3OCarCHarCHarCar), 138.0 (CH3OCarCHarCHarCar),
131.0 (CH3OCarCHarCHarCar), 87.3 (OCH2CH2OCCar), 84.3
(NCH2CH), 70.5 (OCH2CH2OCCar), 64.4 (OCH2CH2OC-
Car), 55.9 (OCH3), 45.2 (NCH2CH) ppm; IR (HBR): ṽ=
3375, 1608, 1508, 1420, 1303, 1176, 1034 cm−1; HRESIMS
m/z (neg): 480.2030 C27H30NO7 (calcd. 480.2028).
1-Butyl-3-hydroxyazetidine-3-carboxamide (11c)
GP2 was followed using 1-benzhydryl-3-hydroxyazetidine-
3-carboxamide 11b (350mg, 1.20 mmol), palladium on
charcoal (10% Pd, 131mg, 0.120 mmol) and butyraldehyde
(0.28 ml, 3.1 mmol) in EtOH (2.0 ml). The crude product
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was purified by flash column chromatography on silica
(eluent: EtOAc/MeOH 95:5+ 3% triethylamine) to afford
the desired compound as amorphous white solid (177 mg,
83%). 1H NMR (400MHz, MeOD): δ (ppm)= 3.65–3.55
(m, 2H, NCH2COH), 3.27–3.22 (m, 2H, NCH2COH),
2.57–2.48 (m, 2H, CH3CH2CH2CH2N), 1.41–1.28 (m, 4H,
CH3CH2CH2CH2N+CH3CH2CH2CH2N), 0.96–0.87 (m,
3H, CH3CH2CH2CH2N);
13C NMR (101MHz, MeOD): δ
(ppm)= 14.4 (CH3CH2CH2CH2N), 21.5 (CH3CH2CH2
CH2N), 30.6 (CH3CH2CH2CH2N), 59.8 (CH3CH2CH2
CH2N), 65.6 (NCH2COH), 72.2 (NCH2COH), 178.4
(CONH2); IR (KBr): ν̃= 3467, 2930, 2361, 1694, 1383,
1252, 1164, 899, 765, 669 cm−1; HRESIMS m/z (pos):
173.1288 C8H17N2O2 (calcd. 173.1285).
1-Butyl-3-hydroxyazetidine-3-carboxylic acid (11d)
GP3 was followed using 1-butyl-3-hydroxyazetidine-3-
carboxamide 11c (88 mg, 0.51 mmol) and barium hydroxide
octahydrate (380 mg, 1.20 mmol) in EtOH/H2O 1:1
(10.0 ml), 24 h, reflux. The desired compound was obtained
as amorphous white solid (84 mg, 95%). 1H NMR
(400MHz, D2O+NaOD): δ (ppm)= 3.58 (d, J= 9.2 Hz,
2H, NCH2COH), 3.21 (d, J= 9.1 Hz, 2H, NCH2COH),
2.54–2.48 (m, 2H, CH3CH2CH2CH2N), 1.36–1.20 (m, 4H,
CH3CH2CH2CH2N+CH3CH2CH2CH2N), 0.89–0.82 (m, 3H,
CH3CH2CH2CH2N);
13C NMR (101MHz, D2O+NaOD): δ
(ppm)= 180.5 (COO), 72.6 (NCH2COH), 64.7 (NCH2COH),
58.8 (CH3CH2CH2CH2N), 29.4 (CH3CH2CH2CH2N), 20.5
(CH3CH2CH2CH2N), 13.4 (CH3CH2CH2CH2N); IR (KBr):
ν̃= 3467, 2930, 2361, 1694, 1383, 1252, 1164, 899, 765,
669 cm−1; HRESIMS m/z (pos): 173.1129 C8H16NO3
(calcd. 174.1125).
Ethyl 2-(1-benzhydryl-3-hydroxyazetidin-3-yl)acetate (11e)
GP1 was followed using LiHMDS in methyl tert-butyl ether
(2.0 ml, 1.9 mmol), EtOAc (0.19 ml, 1.9 mmol) and 1-
benzhydrylazetidin-3-one 11a (424 mg, 1.70 mmol) in THF
(2.0 ml). The crude product was purified by flash column
chromatography on silica (eluent: pentane/Et2O 3:1+ 2%
diethylmethylamine) to afford the desired compound as
amorphous white solid (448 mg, 80%).1H NMR (500MHz,
CDCl3): δ (ppm)= 7.47–7.11 (m, 10H, CHar), 4.39 (s, 1H,
NCHCar), 4.17 (q, J= 7.1 Hz, 2H, COOCH2CH3), 3.79 (s,
1H, OH), 3.34–3.17 (m, 2H, NCH2COH), 3.09–2.98 (m,
2H, NCH2COH), 2.91 (s, 2H, CH2COO), 1.28 (t, J=
7.2 Hz, 3H, COOCH2CH3);
13C NMR (101MHz, CDCl3): δ
(ppm)= 172.9 (COOCH2CH3), 142.3 (NCHCCHCHCH),
128.5 (NCHCCHCHCH), 127.6 (NCHCCHCHCH), 127.3
(NCHCCHCHCH), 77.9 (NCHCar), 67.6 (NCH2COH),
65.2 (NCH2COH), 61.1 (COOCH2CH3), 43.0 (CH2COO),
14.3 (COOCH2CH3); IR (KBr): ν̃= 3404, 2952, 1718,
1451, 1304, 1231, 1080, 902, 749, 706 cm−1; HREIMS m/z
(pos): 325.1662 C20H23NO3 (calcd. 325.1672).
Ethyl 2-(1-butyl-3-hydroxyazetidin-3-yl)acetate (11f)
GP2 was followed using 11e (263mg, 0.810mmol), palla-
dium on charcoal (10% Pd, 84mg, 0.081mmol) and butyr-
aldehyde (0.18ml, 2.0mmol) in EtOH (5.0ml). The crude
product was purified by flash column chromatography on
silica gel (eluent: Et2O+ 3% triethylamine) to afford the
desired compound as colourless oil (195mg, 87%). 1H NMR
(500MHz, CDCl3): δ (ppm)= 4.19 (q, 2H, J= 7.2 Hz,
COOCH2CH3), 3.92 (br s, 1H, OH), 3.43–3.25 (m, 2H,
NCH2COH), 3.14–2.96 (m, 2H, NCH2COH), 2.86 (s, 2H,
CH2COO), 2.52–2.40 (m, 2H, NCH2CH2CH2CH3), 1.37–
1.23 (m, 7H, NCH2CH2CH2CH3+NCH2CH2CH2CH3+
COOCH2CH3), 0.98–0.71 (m, 3H, NCH2CH2CH2CH3);
13C
NMR (126MHz, CDCl3): δ (ppm)= 173.0 (COOCH2CH3),
68.3 (COH), 66.3 (NCH2COH), 61.0 (COOCH2CH3), 59.7
(NCH2CH2CH2CH3), 42.8 (CH2COO), 30.1 (NCH2CH2
CH2CH3), 20.6 (NCH2CH2CH2CH3), 14.3 (COOCH2CH3),
14.2 (NCH2CH2CH2CH3); IR (film): ν̃= 3456, 2958, 2933,
1737, 1465, 1370, 1190, 1031, 948, 879 cm−1; HRESIMS m/z
(pos): 216.1589 C11H22NO3 (calcd. 216.1594).
2-(1-Butyl-3-hydroxyazetidin-3-yl)acetic acid (11g)
GP3 was followed using 11f (34mg, 0.16mmol) and barium
hydroxide octahydrate (201 mg, 0.630mmol) in EtOH/H2O
1:1 (6.0 ml), 19 h, rt. The desired compound was obtained as
amorphous white solid (26 mg, 87%). 1H NMR (400MHz,
D2O+NaOD): δ (ppm)= 3.39–3.33 (m, 2H, NCH2COH),
3.09–3.02 (m, 2H, NCH2COH), 2.61 (s, 2H, CCH2COO),
2.54–2.45 (m, 2H, CH3CH2CH2CH2N), 1.40–1.27 (m, 4H,
CH3CH2CH2CH2N+CH3CH2CH2CH2N), 0.96–0.87 (m,
3H, CH3CH2CH2CH2N);
13C NMR (101MHz, D2O+
NaOD): δ (ppm)= 180.4 (COO), 69.1 (NCH2COH), 66.1
(NCH2COH), 59.6 (CH3CH2CH2CH2N), 46.1 (CH2COO),
29.8 (CH3CH2CH2CH2N), 20.9 (CH3CH2CH2CH2N), 14.3
(CH3CH2CH2CH2N); IR (film): ν̃= 3427, 2930, 2360, 2342,
1583, 1569, 1420, 1108, 912, 686 cm−1; HREIMS m/z (pos):
187.1193 C9H17NO3 (calcd. 187.1203).
Ethyl 2-(1-benzyl-3-hydroxypyrrolidin-3-yl)acetate (12e)
GP1 was followed using LiHMDS in MTBE (2.1 ml,
2.0 mmol), EtOAc (0.20 ml, 2.0 mmol) and 1-
benzylpyrrolidin-3-one 12a (371 mg, 2.10 mmol) in THF
(1.0 ml). The crude product was purified by flash column
chromatography on silica (eluent: pentane/EtOAc 6:4+ 2%
diethylmethylamine) to afford the desired compound as
pale-yellow oil (499 mg, 93%). 1H NMR (500MHz,
CDCl3): δ (ppm)= 7.26 (m, 5H, CHar), 4.17 (q, J= 7.1 Hz,
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2H, COOCH2CH3), 3.64 (s, 2H, CarCH2N), 3.58 (br s, 1H,
OH), 2.80–2.74 (m, 1H, NCH2CH2), 2.71–2.54 (m, 5H,
NCH2CH2+NCH2COH+NCH2COH+ CH2COO),
2.01–1.94 (m, 1H, NCH2CH2), 1.93–1.85 (m, 1H,
NCH2CH2), 1.26 (t, J= 7.1 Hz, 3H, COOCH2CH3); 13C
NMR (126MHz, CDCl3): δ (ppm)= 172.8 (COOCH2CH3),
139.0 (NCH2CCHCHCH), 128.9 (NCH2CCHCHCH),
128.4 (NCH2CCHCHCH), 127.1 (NCH2CCHCHCH), 66.6
(NCH2COH), 60.9 (COOCH2CH3), 60.3 (NCH2Car), 52.9
(NCH2CH2), 44.5 (CH2COO), 39.4 (NCH2CH2), 14.3
(COOCH2CH3); IR (film): ν̃= 3512, 2978, 2796, 1732,
1372, 1189, 1029, 911, 740, 699 cm−1; HREIMS m/z (pos):
263.1525 C15H21NO3 (calcd. 263.1516).
Ethyl 2-(1-butyl-3-hydroxypyrrolidin-3-yl)acetate (12f)
GP2 was followed using 12e (290mg, 1.10 mmol), palladium
on charcoal (10% Pd, 117mg, 0.110mmol) and butyr-
aldehyde (0.30ml, 3.3 mmol) in EtOH (3.5ml). The crude
product was purified by flash column chromatography on
silica gel (eluent: pentane/Et2O 7:3+ 3% diethylmethyla-
mine) to afford the desired compound as colourless oil
(195mg, 77%).1H NMR (400MHz, CDCl3): δ (ppm)=
4.18 (q, J= 7.2Hz, 2H, COOCH2CH3), 3.54 (br s,
1H, OH), 2.81–2.61 (m, 4H, CH2COO+NCH2CH2COH+
NCH2COH), 2.57–2.38 (m, 4H, NCH2CH2COH+
NCH2COH+NCH2CH2CH2CH3), 2.01–1.92 (m, 1H,
NCH2CH2COH), 1.86 (m, 1H, NCH2CH2COH), 1.51–1.40
(m, 2H, NCH2CH2CH2CH3), 1.38–1.25 (m, 5H, COOCH2
CH3+NCH2CH2CH2CH3), 0.91 (t, J= 7.3Hz, 3H, NCH2
CH2CH2CH3);
13C NMR (126MHz, CDCl3): δ (ppm)=
172.8 (COOCH2CH3), 77.6 (COH), 67.0 (NCH2COH), 60.9
(COOCH2CH3), 56.2 (NCH2CH2CH2CH3), 53.1 (NCH2
CH2COH), 44.6 (CH2COO), 39.4 (NCH2CH2COH), 30.9
(NCH2CH2CH2CH3), 20.9 (NCH2CH2CH2CH3), 14.3
(COOCH2CH3), 14.2 (NCH2CH2CH2CH3); IR (film): ν̃=
3442, 2958, 2797, 1735, 1465, 1370, 1190, 1031, 946,
904 cm−1; HREIMS m/z (pos): 229.1673 C12H23NO3 (calcd.
229.1672).
2-(1-Butyl-3-hydroxypyrrolidin-3-yl)acetic acid (12g)
GP3 was followed using 12f (181 mg, 0.790 mmol) and
barium hydroxide octahydrate (500 mg, 1.58 mmol) in
EtOH/H2O 1:1 (8.0 ml), 6 h, rt. The desired compound
was obtained as amorphous off-white solid (153 mg,
96%). 1H NMR (400 MHz, D2O+NaOD): δ (ppm)=
3.90–3.66 (m, 2H, NCH2COH+ NCH2CH2COH),
3.46–3.14 (m, 4H, NCH2COH+NCH2CH2COH+
NCH2CH2CH2CH3), 2.80–2.59 (m, 2H, CH2COO),
2.36–2.03 (m, 2H, NCH2CH2COH+ NCH2CH2COH),
1.78–1.62 (m, 2H, NCH2CH2CH2CH3), 1.39 (h, J=
7.4 Hz, 2H, NCH2CH2CH2CH3), 0.93 (t, J= 7.4 Hz, 3H,
NCH2CH2CH2CH3);
13C NMR (101 MHz, D2O+ NaOD):
δ (ppm)= 180.2 (COOCH2CH3), 78.1 (COH), 65.7
(NCH2COH), 55.9 (NCH2CH2CH2CH3), 52.7 (NCH2CH2
COH), 47.1 (CH2COO), 38.5 (NCH2CH2COH), 29.7
(NCH2CH2CH2CH3), 20.3 (NCH2CH2CH2CH3), 13.4
(NCH2CH2CH2CH3); IR (KBr): ν̃= 3426, 2965, 2876,
2360, 1589, 1395, 1094, 1014, 741, 669 cm−1; HRESIMS
m/z (pos): 202.1439 C10H20NO3 (calcd. 202.1438).
1-Benzyl-3-hydroxypiperidine-3-carboxamide (13b)
1-Benzylpiperidin-3-one hydrochloride 13a (571 mg,
2.50 mmol) was solved in dry CH2Cl2 (4.0 ml). Freshly
distilled triethylamine (0.85 ml, 6.1 mmol) was added and
the brownish suspension was placed in an ultrasound bath
for 15 min. After addition of trimethylsilyl cyanide
(0.80 ml, 6.3 mmol) the reaction mixture was stirred for
48 h, diluted with CH2Cl2 (10.0 ml), filtered through a paper
filter and reduced in vacuum. The oily residue was solved in
CH2Cl2 (7.0 ml) and cooled to 0 °C. Concentrated sulfuric
acid (0.70 ml, 13 mmol) was added and the biphasic mixture
was stirred for 2 h at rt, after which the mixture was cooled
to 0 °C, diluted with H2O (5.0 ml) and alkalized with 25%
ammonium hydroxide solution. Potassium sodium tartrate
(0.50 g) was added and the mixture was extracted five times
with CH2Cl2 (20.0 ml). The combined organic phases were
dried over MgSO4 and reduced in vacuum. The crude
product was purified by flash column chromatography on
silica (eluent: ethyl acetate+ 3% triethylamine) to afford
the desired compound as amorphous off-white solid
(567 mg, 96%).
1H NMR (400MHz, 1,1,2,2-tetra-
chloroethane-d2, 80 °C): δ (ppm)= 7.61 (br s, 1H, NH2),
7.44–7.29 (m, 5H, CHar), 5.46 (br s, 1H, NH2), 3.92 (br s,
1H, OH), 3.64 (s, 2H, NCH2Car), 2.74 (dd, J= 11.3, 1.0 Hz,
1H, NCHaxHeqCOH), 2.63–2.46 (m, 3H, NCHaxHeqCOH+
NCHaxHeqCH2CH2+NCHaxHeqCH2CH2), 1.96 (dddd, J=
13.0, 7.8, 5.1, 1.0 Hz, 1H, NCH2CH2CHaxHeq), 1.89–1.57
(m, 3H, NCH2CH2CHaxHeq+NCH2CHaxHeqCH2+NCH2
CHaxHeqCH2);
13C NMR (101MHz, 1,1,2,2-tetra-
chloroethane-d2, 80 °C): δ (ppm)= 176.8 (CNH2), 137.2
(NCH2CCHCHCH), 128.9 (NCH2CCHCHCH), 128.3
(NCH2CCHCHCH), 127.3 (NCH2CCHCHCH), 71.9
(NCH2COH), 62.6 (NCH2Car), 60.3 (NCH2COH), 52.7
(NCH2CH2CH2), 33.6 (NCH2CH2CH2), 21.5 (NCH2
CH2CH2); IR (KBr): ν̃= 3457, 3409, 2790, 1663, 1274,
1206, 1020, 924, 735, 665 cm−1; HREIMS m/z (pos):
234.1361 C13H18N2O2 (calcd. 234.1363).
1-Butyl-3-hydroxypiperidine-3-carboxamide (13c)
GP2 was followed using 1-benzyl-3-hydroxypiperidine-3-
carboxamide 13b (300 mg, 1.30 mmol), palladium on
charcoal (10% Pd, 138 mg, 0.130 mmol) and butyraldehyde
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(0.29 ml, 3.20 mmol) in EtOH (3.5 ml). The crude product
was purified by flash column chromatography on silica
(eluent: EtOAc+ 3% triethylamine) to afford the desired
compound as amorphous white solid (238 mg, 93%). 1H
NMR (400MHz, 1,1,2,2-tetrachloroethane-d2, 80 °C): δ
(ppm)= 7.65 (br s, 1H, NH2), 5.35 (br s, 1H, NH2), 3.96 (br
s, 1H, OH), 2.63 (d, J= 11.4 Hz, 1H, NCHaxHeqCOH),
2.48–2.28 (m, 5H, CH3CH2CH2CH2N+NCHaxHeqCOH+
NCHaxHeqCH2CH2OH+NCHaxHeqCH2CH2OH),
1.86–1.78 (m, 1H, NCH2CH2CHaxHeqCOH), 1.76–1.57 (m,
2H, NCH2CHaxHeqCH2COH+NCH2CHaxHeqCH2COH),
1.54–1.37 (m, 3H, CH3CH2CH2CH2N+NCH2CH2CHax-
HeqCOH), 1.34–1.20 (m, 2H, CH3CH2CH2CH2N), 0.88 (t,
J= 7.3 Hz, 3H, CH3CH2CH2CH2N); 13C NMR (101MHz,
1,1,2,2-tetrachloroethane-d2, 80 °C): δ (ppm)= 177.4
(CNH2), 72.1 (NCH2COH), 61.0 (NCH2COH), 58.1
(CH3CH2CH2CH2N), 53.1 (NCH2CH2CH2COH), 34.2
(NCH2CH2CH2COH), 29.0 (NCH2CH2CH2OH), 21.4
(CH3CH2CH2CH2N), 14.1 (CH3CH2CH2CH2N);. IR (KBr):
ν̃= 3462, 2955, 2805, 1682, 1454, 1399, 1137, 1019, 917,
659 cm−1; HREIMS m/z (pos): 200.1519 C10H20N2O2
(calcd. 200.1525).
1-Butyl-3-hydroxypiperidine-3-carboxylic acid (13d)
GP3 was followed using 1-butyl-3-hydroxypiperidine-3-
carboxamide 13c (80 mg, 0.40 mmol) and barium hydroxide
octahydrate (254 mg, 0.801 mmol) in EtOH/H2O 1:1
(10.0 ml), 5 h, reflux. The desired compound was obtained
as colourless semi-solid (76 mg, 94%). 1H NMR (400MHz,
D2O+NaOD): δ (ppm)= 2.49 (br d, J= 10.8 Hz, 1H,
NCHaxHeqCH2CH2COH), 2.38 (d, J= 12.0 Hz, 1H,
NCHaxHeqCOH), 2.06–1.90 (m, 3H, CH3CH2CH2CH2N+
NCHaxHeqCOH), 1.72–1.61 (m, 1H, NCHaxHeqCH2CH2-
COH), 1.47–1.20 (m, 4 H, NCH2CH2CHaxHeqCOH+
NCH2CH2CHaxHeqCOH+NCH2CHaxHeqCH2COH+NCH2
CHaxHeqCH2COH), 1.15–1.03 (m, 2H, CH3CH2CH2CH2N),
0.92 (h, J= 7.3 Hz, 2H, CH3CH2CH2CH2N), 0.54 (t, J=
7.3 Hz, 3H, CH3CH2CH2CH2N);
13C NMR (101MHz,
D2O+NaOD): δ (ppm)= 182.1 (COO), 74.3 (NCH2COH),
59.6 (NCH2COH), 57.9 (CH3CH2CH2CH2N), 52.8
(NCH2CH2CH2COH), 32.2 (NCH2CH2CH2COH), 27.2
(CH3CH2CH2CH2N), 20.3 (NCH2CH2CH2COH), 20.2
(CH3CH2CH2CH2N), 13.3 (CH3CH2CH2CH2N); IR (KBr):
ν̃= 3414, 2961, 2874, 1609, 1388, 1179, 1120, 1016, 949,
719 cm−1; HREIMS m/z (pos): 201.1365 C10H19NO3 (calcd.
201.1359).
4-(Butylamino)-2-hydroxybutanoic acid (14b)
GP4 was followed using 14a (134 mg, 1,12 mmol), EtOH
(2.4 ml), KOH (56,1 mg, 2.25 mmol), 1-bromobutane
(139 mg, 1.01 mmol). The desired compound was
obtained as amorphous white solid (155 mg, 79%). 1H
NMR (500MHz, MeOD) δ= 4.00 (t, J= 5.7 Hz, 1H,
CHOH), 3.16–3.09 (m, 2H, OHCCH2CH2N), 2.97 (m, 2H,
NCH2CH2CH2CH3), 2.05 (dtd, J= 14.2, 7.1, 5.5 Hz, 1H,
OHCHCH2), 1.95 (dq, J= 14.5, 6.2 Hz, 1H, OHCHCH2),
1.65 (m, 2H, CH3CH2CH2), 1.43 (m, 2H, CH3CH2CH2),
0.99 (t, J= 7.4 Hz, 3H, CH3CH2CH2 ppm); 13C NMR
(126MHz, MeOD) δ= 180.0 (COOH), 72.0 (COOHCH),
49.8 (NCH2CH2CH2CH3), 46.8 (OHCHCH2CH2), 31.7
(OHCHCH2CH2), 29.4 (NCH2CH2CH2CH3), 20.8
(NCH2CH2CH2CH3), 13.9 (NCH2CH2CH2CH3) ppm; IR
(KBr): ṽ= 3411, 1651, 1359, 1335, 1103, 820 cm−1;




GP6 was followed using 14c (369 mg, 1.20 mmol), tert-
butyl(2-iodoethoxy)diphenylsilane (805 mg, 1.70 mmol),
Ag2CO3 (1.32 g, 4.80 mmol), toluene (2.0 ml), 4d. The
desired compound was obtained as yellow oil (500 mg,
76%). 1H NMR (500MHz, CD2Cl2) δ= 7.83–7.77 (m, 2H,
NCOCarCHarCHar), 7.73–7.66 (m, 6H, CHar), 7.47–7.36 (m,
6H, CHar), 4.02 (dd, J= 8.8, 3.8 Hz, 1H, NCH2CH2CH),
3.86–3.70 (m, 5H, NCH2, SiOCH2CH2), 3.68 (s, 3H,
COOCH3), 3.54 (ddd, J= 9.7, 6.2, 4.2 Hz, 1H,
SiOCH2CH2), 2.11 (dtd, J= 14.4, 7.3, 3.8 Hz, 1H,
NCH2CH2), 2.08–2.00 (m, 1H, NCH2CH2), 1.04 (s, 9H,
CCH3) ppm;
13C NMR (126MHz, CD2Cl2) δ= 172.9
(COOCH3), 168.7 (NCO), 136.2 (Car), 134.5 (Car), 134.2
(Car), 132.7 (Car), 130.2 (Car), 128.2 (Car), 123.6 (Car), 77.8
(NCH2CH2CH), 72.4 (SiOCH2CH2), 63.9 (SiOCH2CH2),
52.3 (COOCH3), 35.1 (NCH2), 32.2 (NCH2CH2), 27.1
(CCH3), 19.6 (CCH3) ppm; IR (film): ṽ= 2932, 1770,
1468, 1396, 1112, 823, 738, 703 cm−1; HRESIMS m/z
(pos): 568.2125 C31H35NO6SiNa (calcd. 568.2126).
Methyl 4-(1,3-dioxoisoindolin-2-yl)-2-(2-hydroxyethoxy)
butanoate (14e)
GP7 was followed using 14d (442 mg, 0.810 mmol), THF/
pyridine 9:1 (10.0 ml), HF-pyridine (116 mg, 4.05 mmol).
The desired compound was obtained as yellow oil (190 mg,
76%). 1H NMR (500MHz, CDCl3) δ= 7.93–7.80 (m, 2H,
CarCHarCHar), 7.80–7.66 (m, 2H, CarCHarCHar), 3.99 (ddd,
J= 13.9, 8.8, 5.0 Hz, 1H, NCH2), 3.92 (dd, J= 9.9, 3.2 Hz,
1H, NCH2CH2CH), 3.81 (dt, J= 14.0, 5.5 Hz, 1H, NCH2),
3.76–3.67 (m, 6H, OCH3, CHOCH2CH2OH), 3.63–3.56 (m,
1H, CHOCH2CH2OH), 2.94 (t, J= 5.7 Hz, 1H, OH), 2.19
(dddd, J= 14.3, 8.7, 5.5, 3.2 Hz, 1H, NCH2CH2), 2.08 (ddt,
J= 14.9, 9.78, 5.25, 5.25 Hz, 1H, NCH2CH2) ppm; 13C
NMR (126MHz, CDCl3) δ= 173.0 (COOCH3), 168.6
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(NCO), 134.3 (CarCHarCHar), 132.2 (CarCHarCHar), 123.5
(CarCHarCHar), 76.7 (NCH2CH2CH), 72.7 (CHOCH2-
CH2OH), 62.0 (CHOCH2CH2OH), 52.3 (OCH3), 34.5
(NCH2CH2), 32.0 (NCH2CH2) ppm; IR (film): ṽ= 3464,
1771, 1760, 1700, 1438, 1398, 1148, 721 cm−1; HRESIMS
m/z (pos): 330.0946 C15H17NO6Na (calcd. 330.0948).
Methyl 4-{1, 3-dioxoisoindolin-2-yl}-2-{2-[tris(4-
methoxyphenyl)methoxy]ethoxy}butanoate (14f)
GP8 was followed using 14e (461 mg, 1.50 mmol), DMF (1
drop), pyridine (4.0 ml), 4,4′,4″-trimethoxytrithyl chloride
(1.03 g, 2.70 mmol). The desired compound was obtained
as a yellow oil (789 mg, 82%). 1H NMR (400MHz, CDCl3)
δ= 7.75–7.80 (m, 2H, NCOCarCHarCHar), 7.73–7.64 (m,
2H, NCOCarCHarCHar), 7.37–7.28 (m, 6H, CH3OCarCH-
arCHar), 6.86–6.77 (m, 6H, CH3OCarCHarCHar), 4.04 (dd,
J= 7.6, 5.0 Hz, 1H, NCH2CH2CH), 3.88 (t, J= 6.9 Hz, 2H,
NCH2), 3.79 (s, 10H, CarOCH3, CHOCH2CH2), 3.72 (s, 3H,
COOCH3), 3.59 (ddd, J= 10.3, 6.2, 4.4 Hz, 1H, CHOCH2
CH2), 3.22 (ddd, J= 10.3, 6.2, 4.3 Hz, 1H, CHOCH2CH2),
3.14 (ddd, J= 10.2, 5.8, 4.4 Hz, 1H, CHOCH2CH2),
2.30–1.88 (m, 2H, NCH2CH2) ppm;
13C NMR (101MHz,
CDCl3) δ= 172.7 (COOCH3), 168.3 (NCO), 158.4
(CH3OCarCHarCHarC), 136.9 (CH3OCarCHarCHarC), 134.0
(NCOCarCHarCHar), 132.3 (NCOCarCHarCHar), 129.9 (CH3
OCarCHarCHarC), 123.3 (NCOCarCHarCHar), 113.2 (CH3
OCarCHarCHarC), 85.8 (OCCar), 77.6 (NCH2CH2CH), 70.5
(CHOCH2CH2), 63.2 (CHOCH2CH2), 55.3 (CarOCH3),
52.1 (COOCH3), 34.9 (NCH2CH2), 31.9 (NCH2CH2) ppm;
IR (film): ṽ= 1748, 1700, 1607, 1508, 1398, 1249, 1176,




GP9a was followed using 14f (192mg, 0.300mmol), MeOH
(3.0ml), 12M NaOH (0.05ml), 1,2-diaminoethane (126mg,
2.10mmol). The desired compound was obtained as amor-
phous white solid (102mg, 69%). 1H NMR (400MHz, 0.1M
NaOD/MeOD) δ= 7.48–7.04 (m, 6H, CH3OCarCHarCHar),
6.99–6.66 (m, 6H, CH3OCarCHarCHar), 3.87 (dd, J= 8.1,
4.4 Hz, 1H, NCH2CH2CH), 3.77 (s, 10H, CHOCH2CH2OC,
OCH3), 3.45 (ddd, J= 10.9, 7.2, 3.9 Hz, 1H, CHOCH2-
CH2OC), 3.27 (m, 1H, CHOCH2CH2OC), 3.19 (m, 1H,
CHOCH2CH2OC), 2.85–2.68 (m, 2H, NCH2CH2), 1.96–1.74
(m, 2H, NCH2CH2) ppm;
13C NMR (101MHz, 0.1M NaOD/
MeOD) δ= 180.9 (COOH), 159.9 (CCarCHarCHarCOCH3),
138.1 (CCarCHarCHarCOCH3), 131.0 (CCarCHarCHarCOCH3),
114.1 (CCarCHarCHarCOCH3), 87.2 (CCarCHarCHarCOCH3),
82.1 (NCH2CH2CH), 70.4 (CHOCH2CH2C), 64.4 (CHOCH2
CH2C), 55.8 (OCH3), 40.1 (NCH2CH2), 37.5 (NCH2CH2)
ppm; IR (KBr): ṽ= 1606, 1505, 1463, 1249, 1175, 1034, 828,
735 cm−1; HRESIMS m/z (neg): 494.2185 C28H32NO7 (calcd.
494.2184).
4-(Butylamino)-3-hydroxybutanoic acid (15b)
GP4 was followed using 15a (238mg, 2.00mmol), EtOH
(2.4ml), KOH (264mg, 4.00mmol), 1-bromobutane (249mg,
1.80mmol). The desired compound was obtained as amor-
phous white solid (263mg, 75%). 1H NMR (500MHz,
MeOD) δ= 4.11 (dtd, J= 8.1, 6.2, 3.9 Hz, 1H,
NCH2CHCH2), 3.09 (dd, J= 12.5, 3.8 Hz, 1H, NCH2CHCH2),
3.02–2.93 (m, 3H, NCH2CHCH2, NCH2CH2CH2CH3), 2.46
(dd, J= 15.6, 6.2 Hz, 1H, COOHCH2), 2.42 (dd, J= 15.6,
6.2 Hz, 1H, COOHCH2), 1.75–1.54 (m, 2H,
NCH2CH2CH2CH3), 1.43 (m, 2H, NCH2CH2CH2CH3), 0.99
(t, J= 7.4 Hz, 3H, NCH2CH2CH2CH3) ppm; 13C NMR
(126MHz, MeOD) δ= 178.7 (COOH), 65.9 (CHOH), 53.9
(OHCHCH2N) 49.2 (NCH2CH2CH2CH3), 43.9 (COOHCH2),
29.4 (NCH2CH2CH2CH3), 20.9 (NCH2CH2CH2CH3), 13.9
(NCH2CH2CH2CH3) ppm; IR (KBr): ṽ= 3223, 1629, 1564,




GP5a was followed using 4-amino-3-hydroxybutanoic acid
15a (1.25 g, 10.3 mmol), phthalic anhydride (1.56 g,
10.3 mmol), MeOH (80.0 ml) and 2M HCl in Et2O
(80.0 ml). The desired compound was obtained as amor-
phous white solid (2.00 g, 74%). 1H NMR (500MHz,
CDCl3) δ= 7.83–7.91 (m, 2H, NCOCarCHarCHar),
7.80–7.70 (m, 2H, NCOCarCHarCHar), 4.37 (ddq, J= 8.56,
7.11, 4.53, 4.49 Hz, 1H, NCH2CHCH2), 3.89 (dd, J= 14.1,
7.1 Hz, 1H, NCH2CHCH2), 3.79 (dd, J= 14.1, 4.5 Hz, 1H,
NCH2CHCH2), 3.72 (s, 3H, OCH3), 3.20 (d, J= 5.1 Hz,
1H, OH), 2.61 (dd, J= 16.5, 4.0 Hz, 1H, NCH2CHCH2),
2.53 (dd, J= 16.5, 8.3 Hz, 1H, NCH2CHCH2) ppm; 13C
NMR (126MHz, CDCl3) δ= 172.4 (COOCH3), 168.7
(NCO), 134.3 (NCOCarCHarCHar), 132.1 (NCOCarCH-
arCHar), 123.6 (NCOCarCHarCHar), 66.8 (NCH2CHCH2),
52.1 (OCH3), 43.0 (NCH2CHCH2), 39.0 (NCH2CHCH2)
ppm; IR (KBr): ṽ= 3450, 1773, 1700, 1610, 1395, 1206,




GP6 was followed using 15c (369mg, 1.20mmol), tert-butyl
(2-iodoethoxy)diphenylsilane (662mg, 1.68mmol), Ag2CO3
(1.32 g, 4.80mmol), toluene (15ml), 4d. The desired
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compound was obtained as a yellow oil (537mg, 82.0%). 1H
NMR (500MHz, CDCl3) δ= 7.83–7.77 (m, 2H, NCO-
CarCHarCHar), 7.73–7.68 (m, 2H, NCOCarCHarCHar),
7.67–7.62 (m, 4H, CHar), 7.43–7.32 (m, 6H, CHar), 4.14 (dq,
J= 7.4, 5.5 Hz, 1H, NCH2CHCH2), 3.90–3.84 (m, 2H,
NCH2CHCH2), 3.78 (dt, J= 9.7, 4.9 Hz, 1H, OCH2CH2Si),
3.75–3.71 (m, 2H, OCH2CH2Si), 3.66 (dt, J= 9.6, 4.5 Hz, 1H,
OCH2CH2Si), 3.61 (s, 3H, OCH3), 2.60 (dd, J= 16.1, 7.5 Hz,
1H, NCH2CHCH2), 2.55 (dd, J= 16.1, 5.5 Hz, 1H,
NCH2CHCH2), 1.00 (s, 9H ppm, SiCCH3) ppm;
13C NMR
(126MHz, CDCl3) δ= 171.5 (COOCH3), 168.4 (NCO), 135.7
(Car), 134.1 (Car), 133.8 (Car), 132.1 (Car), 129.7 (Car), 127.7
(Car), 123.5 (Car), 74.5 (NCH2CHCH2), 71.5 (OCH2CH2OSi),
63.5 (OCH2CH2Si), 51.8 (OCH3), 40.3 (NCH2CHCH2), 38.6
(NCH2CHCH2), 26.9 (SiCCH3), 19.3 (SiC) ppm; IR (film):
ṽ= 2932, 1774, 1770, 1469, 1428, 1396, 1361, 1281, 1192,




GP7 was followed using 15d (442 mg, 0.81 mmol), THF/
pyridine 9:1 (10.0 ml), HF-pyridine (116 mg, 4.05 mmol).
The desired compound was obtained as yellow oil (206 mg,
83%). 1H NMR (500MHz, CD2Cl2) δ= 7.92–7.80 (m, 2H,
NCOCarCHarCHar), 7.80–7.71 (m, 2H, NCOCarCHarCHar),
4.10 (dq, J= 9.0, 4.5 Hz, 1H, NCH2CHCH2), 3.87 (dd, J=
14.3, 4.9 Hz, 1H, NCH2CHCH2), 3.80 (dd, J= 14.3,
4.5 Hz, 1H, NCH2CHCH2), 3.73 (ddd, J= 10.3, 5.9,
3.1 Hz, 1H, OCH2CH2OH), 3,66 (s, 3H, OCH3), 3.65 (ddd,
J= 10.3, 5.9, 2.8 Hz, 1H, OCH2CH2OH), 3.60 (ddd, J=
12.3, 6.1, 2.8 Hz, 1H, OCH2CH2OH), 3.56 (ddd, J= 12.2,
6.0, 3.0, 1H, OCH2CH2OH), 2.76 (t, J= 6.3 Hz, 1H, OH),
2.59 (dd, J= 16.4, 4.3 Hz, 1H, NCH2CHCH2), 2.52 (dd,
J= 16.4, 8.7 Hz, 1H, NCH2CHCH2) ppm; 13C NMR
(126MHz, CD2Cl2) δ= 172.3 (COOCH3), 169.1 (NCO),
134.7 (NCOCarCHarCHrar), 132.5 (NCOCarCHarCHar),
123.8 (NCOCarCHarCHar), 75.3 (NCH2CHCH2), 72.6
(OCH2CH2OH), 62.3 (OCH2CH2OH), 52.3 (OCH3), 40.9
(NCH2CHCH2), 38.6 (NCH2CHCH2) ppm; IR (film): ṽ=
3472, 2951, 1773, 1770, 1467, 1397, 112, 725 cm−1;




GP8 was followed using 15e (338mg, 1.10mmol), DMF (1
drop), pyridine (4.0ml), 4,4′,4″-trimethoxytrithyl chloride
(753mg, 1.98mmol). The desired compound was obtained as
yellow oil (520mg, 74%). 1H NMR (400MHz, CD2Cl2) δ=
7.89–7.76 (m, 2H, NCOCarCHarCHar), 7.76–7.65 (m, 2H,
NCOCarCHarCHar), 7.32–7.18 (m, 6H, CH3OCarCHarCHar),
6.86–6.72 (m, 6H, CH3OCarCHarCHar), 4.13 (dq, J= 7.2,
5.6 Hz, 1H, NCH2CHH2), 3.89 (dd, J= 14.1, 5.5 Hz, 1H,
NCH2CHCH2), 3.81 (dd, J= 14.0, 5.7 Hz, 1H, NCH2CHH2),
3.77 (s, 9H, CarOCH3), 3.76 (ddd, J= 10.2, 5.6, 4.4 Hz, 1H,
OCH2CH2OCCar), 3.64 (ddd, J= 10.2, 5.6, 4.5 Hz, 1H,
OCH2CH2OCCar), 3.59 (s, 3H, COOCH3), 3.10 (ddd, J=
12.2, 5.6, 4.3 Hz, 1H, OCH2CH2OCCar), 3.07 (ddd, J= 12.2,
5.6, 4.2 Hz, 1H, OCH2CH2OCCar), 2.62 (dd, J= 16.0, 7.1 Hz,
1H, NCH2CHCH2), 2.56 (dd, J= 16.0, 5.4 Hz, 1H,
NCH2CHCH2) ppm;
13C NMR (101MHz, CD2Cl2) δ= 171.8
(COOCH3), 168.8 (NCO), 158.9 (CH3OCar), 137.4
(CCarCHar), 134.6 (NCOCarCHarCHar), 132.6 (NCOCar), 130.3
(CH3OCarCHarCHar), 123.7 (NCOCarCHarCHar), 113.5
(CH3OCarCHarCHar), 86.1 (CCarCHarCHar), 75.1
(NCH2CHCH2), 70.3 (OCH2CH2OCCar), 63.7 (OCH2-
CH2OCCar), 55.7 (CarOCH3), 52.1 (COOCH3), 41.0
(NCH2CHCH2), 38.9 (NCH2CHCH2) ppm; IR (film): ṽ=
1773, 1607, 1507, 1396, 1249, 1175, 1033, 828 cm−1; HRE-
SIMS m/z (pos): 662.2365 C37H37NO9Na (calcd. 662.2366).
4-Amino-3-{2-[tris(4-methoxyphenyl)methoxy]ethoxy}
butanoic acid (15g)
GP9b was followed using 15f (141mg, 0.220mmol), MeOH
(3.0ml), 12M NaOH (0.05ml), 1,2-diaminoethane (92,6mg,
1.54mmol). The desired compound was obtained as amor-
phous white solid (75mg, 69%). 1H NMR (400MHz, 0.1M
NaOD/MeOD) δ= 7.36–7.21 (m, 6H, CH3OCarCHarCHar),
6.90–6.69 (m, 6H, CH3OCarCHarCHar), 3.82–3.72 (m, 11H,
CH2CHCH2, OCH3, CHOCH2CH2OC), 3.63 (ddd, J= 10.35,
6.16, 3.94 Hz, 1H, CHOCH2CH2OC), 3.28–3.09 (m, 2H,
CHOCH2CH2OC), 2.81 (dd, J= 13.4, 3.5 Hz, 1H,
NCH2CHCH2), 2.64 (dd, J= 13.4, 7.2 Hz, 1H, NCH2CHCH2),
2.51 (dd, J= 14.2, 6.1 Hz, 1H, NCH2CHCH2), 2.25 (dd, J=
14.2, 7.3 Hz, 1H, NCH2CHCH2) ppm;
13C NMR (101MHz,
0.1M NaOD/MeOD) δ= 180.2 (COOH), 159.8 (CCarCHar
CHarCOCH3), 138.0 (CCarCHarCHarCOCH3), 130.9 (CCar
CHarCHarCOCH3), 114.1 (CCarCHarCHarCOCH3), 87.1 (CCar
CHarCHarCOCH3), 80.8 (NCH2CHCH2), 70.1 (CHOCH2
CH2C), 64.6 (CHOCH2CH2C), 56.0 (, OCH3), 46.2
(NCH2CH), 42.2 (NCH2CHCH2) ppm; IR (KBr): ṽ= 3375,
1606, 1505, 1463, 1249, 1175, 1034, 828, 735 cm−1; HRE-
SIMS m/z (neg): 494.2196 C28H33NO7 (calcd. 494.2184).
Biological evaluation
HEK cells
HEK293 cells were purchased from the American Type Cul-
ture Collection (ATCC) specified as ATCC-CRL-1573 (Lot
57954093). The stably mGAT1, mGAT2, mGAT3 or mGAT4
expressing HEK293 cell lines were generated as described
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previously (Kragler et al. 2005, 2008). These cell lines were
cultivated till reaching confluencies >85% (up to passage 25)
and immediately used after detachment and washing.
[3H]GABA uptake assays
The [3H]GABA uptake assays were performed as reported
(Kragler et al. 2005, 2008) in a 96‐well plate format with
intact HEK293 cells expressing mGAT1, mGAT2, mGAT3
and mGAT4, respectively.
MS Binding Assays
The MS Binding Assays were performed as reported
(Zepperitz et al. 2006) with mGAT1 membrane prepara-
tions obtained from a stable HEK293 cell line and NO711
as unlabelled marker in competitive binding experiments.
Results and discussion
Synthesis
Synthesis of the cyclic N-butylamino acid derivatives
For the synthesis of the cyclic N-butylhydroxyamino acids
11d, 11g, 12g, and 13d we intended to start from the benzyl- or
benzhydryl-protected cyclic aminoketones 11a, 12a and 13a,
respectively. Reaction of 11a and 13a with tetramethylsilyl
cyanide followed by acidic hydrolysis of the thus to be formed
TMS-protected cyanohydrines should furnish the correspond-
ing α-hydroxycarboxamides 11b and 13b. Likewise, reaction
of the cyclic aminoketones 11a and 12a with lithium 1-
ethoxyethen-1-olate should lead to the β-hydroxyesters 11e and
12e. Deprotection of the amino nitrogen atom of 11b, 11e, 12e,
and 13b, followed by introduction of a n-butyl rest via
reductive amination and hydrolysis of the carboxamide and
ester function, respectively, should finally furnish the desired
free amino acids 11d, 11g, 12g, and 13d.
Synthesis of the cyclic α-hydroxycarboxamide 11b
was performed according to literature (Lamb 2008). The
same reaction sequence was applied for the synthesis of
its ring-expanded analogue 13b. Hence, the N-
benzylpyrrolid-3-one 13a was reacted with trimethylsi-
lyl cyanide to give the respective TMS-protected cya-
nohydrine. Due to the lability of the TMS ether function,
the TMS-protected cyanohydrine was not purified and
characterized, but used for the next reaction step, the
hydrolysis with concentrated sulfuric acid. This gave the
corresponding α-hydroxycarboxmide 13b in an excellent
yield of 96% over both reaction steps. The
β-hydroxyesters 11e and 12e were obtained in good
yields of 80–93% from the cyclic aminoketones 11a and
12a by reaction with lithium 1-ethoxyethen-1-olate,
which was generated from ethyl acetate and LiHMDS at
low temperature (Scheme 3).
Scheme 3 Synthesis of the cyclic hydroxyamino acids 11d, 11g, 12d and 13d. Reagents and conditions: a 1. Trimethylsilyl cyanide (2.5 eq),
CH2Cl2, rt, 48 h; 2. sulfuric acid (5.2 eq), CH2Cl2, 0 °C–rt, 2 h. b 1. LiHMDS (1.0 eq), ethyl acetate (1.0 eq), methyl tert-butyl ether, −78 °C,
25 min, 2. 11a/12a, THF, −78 °C to −10 °C. c H2 (10 bar), n-butyraldehyde (2.5 eq), 10% palladium on charcoal (0.1 eq), rt, 16 h; d barium
hydroxide octahydrate (2.0–2.4 eq), EtOH/H2O 1:1, rt or reflux
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Next, the carboxamide and ester derivatives 11b, 11e, 12e
and 13b were subjected to deprotection of the nitrogen atom
and subsequent n-butylation, accomplished in a single reaction
step by exposing the compounds to hydrogen (10 bar) in pre-
sence of palladium on cabon and 2.0–2.4 equivalents of n-
butyraldehyde. This furnished the respective N-butyl deriva-
tives 11c, 11f, 12f, and 13c in yields of 77–93%. Finally, after
basic hydrolysis and workup (barium hydroxide, carbon
dioxide workup), the free amino acids 11d, 11g, 12g, and 13d
were hence obtained in yields of 87–96% (Scheme 3).
Synthesis of the acyclic N-butylamino acid
derivatives
For the synthesis of the N-butyl derivatives 7b, 14b, and
15b from the cyclic hydroxyamino acids 7a, 14a, and
15a, a specialized procedure developed for the mono-
butylation of β-alanine (Santimukul and Perez 2011) was
followed. When according to this procedure 7a, 14a, and
15a were treated with n-bromobutane in a mixture of
methanol and water under reflux the desired test com-
pounds 7b, 14b, and 15b were obtained in yields of
75–79% (Scheme 4).
Synthesis of O-alkylated hydroxyamino acid
derivatives
Since the unsubstituted hydroxyamino acids 7a, 14a, and
15a had been found to exhibit higher inhibitory potencies at
all GAT subtypes than the corresponding N-butyl
derivatives 7b, 14b, and 15b (see chapter 3 “biological
evaluation”, Table 3), also the respective amino acid deri-
vatives with an tris(4-methoxyphenyl)methyloxyethyl
attached to the hydroxy function of the parent compounds
should be included in this study.
As starting compounds for this synthesis of the target
compounds 7g, 14g, and 15g, the derivatives 7c, 14c, and
15c seemed well suited, as they should allow a selective
functionalization of the OH group as the carboxylic acid
and the amino moieties in 7g, 14g, and 15g are protected in
form of ester and phthalimidic moieties, respectively. The
preparation of 14c has been described in literature (Farkas
et al. 2009), the synthesis of 7c and 15c should be
accomplished in an analogous manner. Based on these
starting materials, 7c, 14c, and 15c, in the next steps first a
2-hydroxyethyl residue should be attached to the free OH
function to serve as linker to the lipophilic domain of the
target compound. The trityl based lipophilic moiety should
be introduced only after that, as the reaction conditions
required for the formation of the first ether function were
thought to cause side reactions if the terminal trityl moiety
were already present. Deprotection of the carboxylic acid
and the amino group in 7f, 14f, and 15f should finally lead
to the target compounds 7g, 14g, and 15g.
The synthesis of 14c was accomplished according to
literature (Farkas et al. 2009) by first reacting 14a with
phthalic anhydride to protect the terminal amino group as
phthalimide moiety, followed by etherification of the
carboxyl group to give the corresponding carboxylic acid
ester, the overall product being 14c. Applying the same
Scheme 4 N-Butylation of the acyclic hydroxyamino acids 7a, 14a, and 15a, furnishing 7b, 14b, and 15b. Reagents and conditions: a 1-
bromobutane (0.9 eq), KOH (2.0 eq), EtOH/H2O, rt, 16 h
1334 Medicinal Chemistry Research (2020) 29:1321–1340
Table 3 Results of the biological evaluation
Entry Compound Binding affinity (pKi ± SEM)
a GABA uptake inhibition (pIC50 ± SEM)
b
mGAT1 mGAT2 mGAT3 mGAT4
1 16 3.36 ± 0.02 4.11 ± 0.08 3.23 81% 3.32 ± 0.04
2 7a 2.43 ± 0.03 2.33 ± 0.05 3.38 ± 0.11 4.87 ± 0.05 4.78 ± 0.14
3 7b 86% 101% 92% 3.54 ± 0.04 3.26 ± 0.10
4 7g 85% 63% 57% 63% 60%
5 11c 101% 83% 105% 92% 96%
6 11d 97% 89% 3.38 ± 0.08 72% 85%
7 11f 106% 66% 91% 82% 88%
8 11g 93% 79% 78% 80% 99%
9 12f 88% 104% 96% 86% 71%
10 12g 93% 94% 3.17 103% 105%
11 13c 103% 109% 84% 79% 90%
12 13d 97% 96% 104% 85% 91%
13 14a 3.61 ± 0.05 4.99 ± 0.08 3.25 ± 0.02 4.73 ± 0.10 4.64 ± 0.03
14 14b 107% 79% 59% 3.21 ± 0.08 107%
15 14g 61% 78% 66% 94% 73%
16 15a 2.31 4.06 ± 0.08 4.19 ± 0.01 4.41 ± 0.09 4.37 ± 0.14
17 15b 94% 100% 76% 3.59 ± 0.07 3.42 ± 0.12
18 15g 74% 67% 67% 54% 3.95
aResults of the MS Binding Assays are given as pKi ± SEM. Percent values represent remaining specific NO711 binding in presence of 100 µM test
compound
bResults of the [3H]GABA uptake assays are given as pIC50 ± SEM. Percent values represent remaining [
3H]GABA uptake in presence of 100 µM test
compound
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procedure to 7a and 15a, the analogous compounds 7c
and 15c could be obtained in yields of 73% (7c) and 72%
(15c) (Scheme 5).
The required hydroxylethylation of the OH function
could be realized by treatment of 7c, 14c, and 15c with 2-
iodoethoxy-TBDPS in the presence of Ag2CO3 furnishing
the corresponding ethers 7d, 14d, and 15d in good yields of
76–82%. Removal of the TBDPS protecting group by
treatment with HF-pyridine yielded in the free alcohols 7e,
14e, and 15e (76–84%), which upon reaction with 4,4′,4″-
trimethoxytrityl chloride, gave the trityl derivatives 7f, 14f,
and 15f (74–90%, Scheme 6).
The final deprotection of the amino and the carboxylic
acid function of 7f, 14f, and 15f in order to obtain the free
amino acids 7g, 14g, and 15g was first attempted in a two-
step reaction sequence. Hydrazinolysis of the phthalimide
moiety should liberate the terminal amino group, and sub-
sequently hydrolysis of the methyl ester function under
alkaline conditions (NaOH) the carboxylic acid moiety.
Unfortunately, when the primary amine was formed in the
first reaction step, it immediately reacted with the methyl
ester function leading to the formation of the corresponding
lactame, which could not be cleaved again without
destruction of the molecule. Hence, the sequence of the
deprotection was altered applying first NaOH to hydrolyse
the methyl ester function. Thereby, also the phthaloyl group
protecting the amino function was partially cleaved leading
to the corresponding phthalamide moieties. Still, the free
amino acids 7g, 14g, and 15g could be obtained by sub-
jecting the thus obtained crude reaction product without
prior isolation to heating with 1,2-diaminoethane. This
furnished the desired target compounds 7g, 14g, and 15g in
yields of 69–83% over both reaction steps (Scheme 6).
Biological evaluation
The amino acids 7a, 7b, 7g, 11d, 11g, 12g, 13d, 14a, 14b,
14g, 15a, 15b, 15g, as well as the carboxamide and ester
derivatives 11c, 11f, 12f, and 13c were tested for their inhi-
bitory potencies on the four GABA transporter subtypes
mGAT1–4 in a [3H]GABA uptake assay previously devel-
oped by our group (Kragler et al. 2008) The tests were per-
formed in a standardized manner in triplicates using HEK293
cell lines, each expressing one of the four GAT subtypes. In
addition, binding affinities towards mGAT1 were examined
employing a standardized MS Binding Assay with NO711 as
native MS marker (Zepperitz et al. 2006). The results are
summarized in Table 3. Inhibitory potencies and binding
affinities of the tested compounds are represented as pIC50
and pKi, respectively. Each test compound was characterized
in three independent experiments performed in triplicates and
the standard error of mean (SEM) is given. If the determi-
nation of the pIC50 value proved not feasible due to low
inhibitory potency, as percentage of the remaining [3H]
GABA uptake at 100 µM concentration of the test compound.
Correspondingly, the percentage of remaining MS marker is
Scheme 5 Synthesis of the protected amino acid derivatives 7c, 14c, and 15c. Reagents and conditions: a 1. Phthalic anhydride (1.0 eq), 140 °C,
30 min; 2. MeOH, 2M HCl in Et2O, rt
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given in cases when the tested compound caused only a minor
reduction of the MS marker binding.
As can be seen from the data in Table 3, the unsub-
stituted α- and β-hydroxyamino acids 7a, 14a, and 15a,
which served as the starting material for the synthesis of the
N-butyl derivatives 7b, 14b, and 15b, exhibit considerable
inhibitory activities at most of the GAT subtypes, with the
pIC50 values ranging from 4.06 ± 0.08 (15a, mGAT1, Table
3, entry 16) to 4.99 ± 0.08 (14a, mGAT1, Table 3, entry
13). Only for 7a at mGAT1 (pIC50= 2.33 ± 0.05, Table 3,
entry 2) and at mGAT2 (pIC50= 3.38 ± 0.11, Table 3, entry
2) and 14a (pIC50= 3.25 ± 0.02, Table 3, entry 13) at
mGAT2 distinctly lower pIC50 values were found.
As compared with the unsubstituted α- and
β-hydroxyamino acids 7a, 14a, and 15a the N-butyl deri-
vatives 7b, 14b, and 15b are characterized by lower inhi-
bitory activity throughout, which might indicate that the
binding pose in which the amino nitrogen atom is oriented
towards the cytosol, as postulated by molecular modelling
experiments performed by Wein et al. (Wein et al. 2016) is
energetically disfavoured. As reported in Table 3, entry 3,
N-butylisoserine (7b) shows a pIC50 value of 3.26 ± 0.10 at
mGAT4, which is on par with the value reported for race-
mic N-butylnipecotic acid 16 (pIC50= 3.32 ± 0.04, Table 3,
entry 1), which can be considered as a reasonable reference
point since nipecotic acid constitutes the amino acid partial
structure of many important GAT inhibitors including tia-
gabin (4, Table 1, entry 5) and (S)-SNAP-5114 (5, Table 1,
entry 6). Interestingly, 7b exerts a somewhat higher inhi-
bitory potency at mGAT3 (pIC50= 3.54 ± 0.04) than at
mGAT4, whereas the activity at mGAT1-2 can be con-
sidered negligible ([3H]GABA at 100 µM= 101% and
95%, respectively). This selectivity pattern deviates sig-
nificantly from that of the reference compound 16, which
exerts its highest inhibitory potency at mGAT1 (pIC50=
4.11 ± 0.08) while being less active at mGAT2 (pIC50=
3.23) and mGAT3 ([3H]GABA at 100 µM= 81%).
For the homologue of 7b, compound 14b, formally
derived from 7b by inserting a methylene group at the end
of the carboxyl acid carbon chain, the potency at mGAT4
has decreased distinctly, i.e. to a value below the identifi-
cation threshold ([3H]GABA at 100 µM= 107%, Table 3,
entry 14). The biological activity at mGAT3 on the other
hand is only slightly reduced from 3.54 ± 0.04 for 7b to
3.21 ± 0.08 for 14b. The effects exerted at mGAT1 and
mGAT2 are slightly higher as compared with 7b, with the
remaining [3H]GABA uptake for 14b amounting to 79%
(mGAT1) and 59% (mGAT2), respectively.
Scheme 6 Synthesis of acyclic amino acid derivatives comprising a 4,4′,4″-trimethoxytrityl moiety, which is linked to the 2- or 3-position of the
carbon chain via an OCH2CH2O spacer (7g, 14g and 15g). Reagents and conditions: a Ag2CO3 (4.0 eq), tert-butyl(2-iodoethoxy)diphenylsilane
(1.4 eq), toluene, reflux; b HF-pyridine (5.0 eq), THF/pyridine 9:1, 0 °C–rt; c 4,4′,4″-trimethoxytrityl chloride (1.8 eq.), pyridine, dimethylfor-
mamide (cat.), rt; d 1. 1M NaOH (2.0 eq), MeOH, rt, 16 h; 2. 1,2-diaminoethane (7.0 eq), microwave, 140 °C, 16 h
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By contrast, if the elongation of the carbon chain is
performed by inserting a methylene group between the
carbon carrying the OH function and the carboxylic acid
group (15b, Table 3, entry 17), the pIC50 value at mGAT4
increases nominally from 3.26 ± 0.10 for 7b to 3.42 ± 0.12
for 15b, while the effect exerted at mGAT3 remains unal-
tered (15b: pIC50= 3.59 ± 0.07, 7b: pIC50= 3.54 ± 0.04).
As is the case with N-butylisoserine (7b), 15b exhibits
no determinable inhibition at mGAT1 ([3H]GABA at
100 µM= 100%), whereas a slight effect at mGAT2 is
found ([3H]GABA at 100 µM= 76%).
Unexpectedly, rigidization of the N-butylisoserine (7b)
molecule by linking the C-2 atom with the nitrogen atom
via a methylene bridge, resulting in azetidine heterocycle
11d, leads to a compound which exerts its highest inhibitory
potency at mGAT2 (pIC50= 3.38 ± 0.08, Table 3, entry 6).
At the same time the effects of 11d at the other GATs are
minor, the [3H]GABA uptake amounting to 72% (mGAT3),
85% (mGAT4), and 89% (mGAT1). Formal enlargement of
the azetidine ring present in 11d to a piperidine ring causes
the inhibitory potency at mGAT2 to completely vanish
(13d, [3H]GABA at 100 µM= 104%, Table 3, entry 12). In
addition, the activity exerted at the other GAT subtypes is
extremely low, the values for the remaining [3H]GABA
uptake at 100 µM being 96% (mGAT1), 85% (mGAT3),
and 91% (mGAT4), respectively. As compared with its
desoxy analogoue N-butylnipecotic acid (16, Table 3, entry
1), this constitutes a distinct decline of inhibitory potency at
all GATs, hence demonstrating that the introduction of a
hydroxy group into the 3-position of the nipecotic acid
scaffold is associated with a strong reduction of biological
activity.
11c and 13c, the carboxamide derivatives of the cyclic
N-butyl-α-hydroxyamino acids 11d and 13d, were also
tested for their inhibitory potential at all GAT subtypes.
11c, comprising an azetidine heterocyle, is characterized by
marginal or non-detectable inhibitory potencies (Table 3,
entry 5), the values of the remaining [3H]GABA uptake at
100 µM test compound concentration ranging from 83%
(mGAT1) to nominally 105% (mGAT2). Likewise, 13c
(Table 3, entry 11), which features a piperidine ring, redu-
ces the [3H]GABA uptake to 84% (mGAT2), 79%
(mGAT3) and 90% (mGAT4), whereas it appears to be
completely inactive at mGAT1 at 100 µM, the [3H]GABA
uptake amounting nominally to 109%.
Exhibiting pIC50 values of 3.59 ± 0.07 at mGAT3 and
3.42 ± 0.12 at mGAT4, 15b showed the highest inhibitory
activity of the tested open-chain N-butylhydroxyamino
acids (Table 3, entry 17). Hence, analogues of 15b that have
the structure of the molecule rigidized by integrating the
amino nitrogen atom and parts of the carbon chain into an
azetidine (11g) and pyrrolidine ring (12g), respectively,
seem of interest. However, 11g was found to exert only
minor inhibitory potency at mGAT1-3, with the values for
the remaining [3H]GABA uptake at 100 µM lying between
78% (mGAT2) and 80% (mGAT3) and the inhibitory
potency at mGAT4 being negligible ([3H]GABA uptake at
100 µM= 99%, Table 3, entry 8). By contrast, the open-
chain analogue 15b exerted reasonable inhibitory potencies
at mGAT3 (pIC50= 3.59 ± 0.07, Table 3, entry 17) and at
mGAT4 (pIC50= 3.42 ± 0.12).
Linking the C-3 atom and the amino nitrogen atom of
15b via a C2-bridge, resulting in a pyrrolidine substructure,
is likewise accompanied by a complete loss of inhibitory
potency at mGAT3-4, the values for the remaining [3H]
GABA uptake being nominally 103% and 105%, respec-
tively (12g, Table 3, entry 10). However, the compound
exerts some activity at mGAT2 (pIC50= 3.17). For
mGAT1, a value of 94% remaining GABA uptake at
100 µM was determined, which is consistent with the par-
ent compound 15b not showing any effect at this subtype
(15b, remaining [3H]GABA uptake= 100%, Table 3,
entry 17).
11f and 12f, the ester derivatives of the cyclic amino
acids 11g and 12g, were also tested for their inhibitory
potency at mGAT1–4. As shown in Table 3, entry 7, the
azetidine derivative 11f exhibits some activity at mGAT1
(remaining [3H]GABA uptake= 66%), whereas the effect
at mGAT2-4 is less pronounced (91%, 82% and 88%,
respectively). 12f (Table 3, entry 9), which is the ester
derivative of 12g, is characterized by minor or negligible
inhibitory activity at all GAT subtypes, the values of the
remaining [3H]GABA uptake being 104% (mGAT1),
96% (mGAT2), 86% (mGAT3) and 71% (mGAT4),
respectively.
Since both the cyclic and acyclic N-butyl derivatives of
7a, 14a, and 15a were found to exhibit distinctly lower
inhibitory potencies than the parent compounds con-
sistently, derivatives of 7a, 14a, and 15a were synthesized
which have the alcohol function linked to a C2 spacer
bearing a 4,4′,4″-trimethoxytrityloxy moiety. In theory, this
would allow the amino acid subunit to keep the more
favourable orientation towards the intracellular space, while
at the same time enabling interactions between the lipo-
philic domain and the extracellular vestibule, which are
thought to significantly increase inhibitory potency and
selectivity in case of nipecotic acid derivatives such as (S)-
SNAP-5114 (5, Table 1, entry 6). Unfortunately, the
introduction of the lipophilic domain into the scaffold of 7a,
14a, and 15a caused a reduction of inhibitory potency. For
the derivatives resulting from this modification (7g, 14g,
and 15g) the values for the [3H]GABA uptake at 100 µM
test compound concentration remained at >50% at all
transporter subtypes, equating to pIC50 values <4.0. More-
over, 7g and 15g were found to display only negligible
subtype selectivity. In particular, 7g reduced the [3H]GABA
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uptake to 63% (mGAT1), 57% (mGAT2), 63% (mGAT3)
and 60% (mGAT4), respectively (Table 3, entry 4). Like-
wise, the remaining [3H]GABA uptake in presence of
100 µM 15g ranged from 54% (mGAT3) to 67% (mGAT1
and mGAT2). For mGAT4, a pIC50 value just short below
4.0 was determined (pIC50= 3.95, Table 3, entry 18). 14g
(Table 3, entry 15) was found to reduce the [3H]GABA
uptake to 78% (mGAT1), 66% (mGAT2), 94% (mGAT3)
and 73% (mGAT4), respectively.
For all test substances the binding affinities at mGAT1
were found to be very low as compared with the reference
compound 16 (pKi= 3.36 ± 0.02, Table 3, entry 1), the only
exception being 14a (pKi= 3.61 ± 0.05, Table 3, entry 11).
Conclusion
A series of cyclic and acyclic hydroxyamino acid deriva-
tives was synthesized and biologically evaluated for their
potential as amino acid subunits in GAT inhibitors. Among
the compounds synthesized for this study, we identified 1-
butyl-3-hydroxyazetidine-3-carboxylic acid and, even more
so, 2-(1-butyl-3-hydroxypyrrolidin-3-yl)acetic acid to be
selective and moderately potent inhibitors of mGAT2, with
the respective pIC50 values amounting to 3.17 and 3.38 ±
0.08, respectively.
Whereas the cyclic and hence more rigid N-
butylhydroxyamino acids displayed only weak inhibitory
potency at mGAT3 and mGAT4, moderate activity was
observed in case of some acyclic compounds tested for this
study. In particular, 4-(butylamino)-3-hydroxybutanoic acid
(pIC50= 3.42 ± 0.12) and N-butylisoserine (pIC50= 3.26 ±
0.10) were found to be equal to N-butylnipecotic acid
(pIC50= 3.32) in terms of inhibitory potency at mGAT4,
while being distinctly stronger mGAT3 inhibitors with the
pIC50 values amounting to 3.59 ± 0.07 and 3.54 ± 0.04,
respectively (N-butylnipecotic acid: [3H]GABA uptake at
100 µM= 81%). At the same time, both compounds exert
no identifiable inhibitory effect at mGAT1 under the test
conditions ([3H]GABA uptake at 100 µM= 100% and
101%, respectively), hence deviating strongly from the
reference compound N-butylnipecotic acid, which con-
stitutes a potent inhibitor of this GAT subtype (mGAT1:
pIC50= 4.11 ± 0.08). 4-(Butylamino)-3-hydroxybutanoic acid
and N-butylisoserine might thus be suitable alternatives to
the nipecotic acid subunit in mGAT3/4 inhibitors.
Interestingly, the pIC50 values of the unsubstituted, open-
chained hydroxyamino acids are in most cases more than
one log unit higher at all GAT subtypes than the values of
the respective N-butyl analogues, indicating that N-
derivatisation might carry an energy penalty by forcing
the compound into a less favourable binding pose. There-
fore, each of the hydroxyamino acids was derivatized by
linking the alcohol function to a C2 spacer bearing a 4,4′,4″-
trimethoxytrityloxy moiety, which is a common structural
motif of mGAT4 inhibitors such as (S)-SNAP-5114. In
theory, this would allow the amino acid subunit to adapt the
more favourable binding pose, while at the same time
enabling interactions between the target and the lipophilic
domain. Unfortunately, the resulting compounds displayed
poor inhibitory potency and selectivity as compared with
the unsubstituted hydroxyamino acids and, even more so, as
compared with (S)-SNAP-5114.
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